People with head and neck cancer did not receive a statistically-significant benefit from treatment with Merck & Co’s (NYSE: MRK) Keytruda (pembrolizumab) in the KEYNOTE-412 trial.
The late-stage study has been evaluating the checkpoint blocker with concurrent chemoradiation therapy, followed by Keytruda as maintenance therapy, for people with unresected locally advanced cancer.
While there was an improvement in event-free survival (EFS) in the final analysis, it was not enough for the study to meet the primary endpoint.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze